AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16571960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg or greater
Number of subjects: 27
Study 16571960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16571960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 27
Study 12749830 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 1600/45 microg
Number of subjects: 14
Study 12749830 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 45 microg
Number of subjects: 14
Study 12749830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11764220 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (COX-2 specific inhibitor)
Number of subjects: 0
Study 11764220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9432788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative dosage increased by 50% (single dose - 6 Gy; total dose - 30 Gy; 54 isoGy) for stomach cancer
Number of subjects: 1280
Study 9432788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative dosage increased by 25% (single dose - 5 Gy; total dose - 25 Gy; 40 isoGy) for colonic cancer
Number of subjects: 1280
Study 9432788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative irradiation with a single HRT dose of 10 Gy (28 isoGy) for breast tumors reduced time of irradiation 4 times
Number of subjects: 1280
Study 9432788 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy as a control procedure - 357 patients
Number of subjects: 1280
Study 8217066 — intervention group
Group type: EXPERIMENTAL
Intervention: levoprotiline
Number of subjects: 58
Study 8217066 — intervention group
Group type: EXPERIMENTAL
Intervention: maprotiline
Number of subjects: 58
Study 8217066 — intervention group
Group type: COMPARATOR
Intervention: complementary drug treatment for non-responders
Number of subjects: 58
Study 10282583 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (drugs with computer-generated prompts)
Number of subjects: 10
Study 10282583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prompts)
Number of subjects: 10
Study 29326087 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (3-month duration, focused on strength, balance, stretching exercises, and walking recommendations)
Number of subjects: 112
Study 29326087 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program
Number of subjects: 112
Study 29326087 — intervention group
Group type: COMPARATOR
Intervention: Routine activities (Control Group)
Number of subjects: 112
Study 26885697 — intervention group
Group type: EXPERIMENTAL
Intervention: AlgaeCal calcium supplement (AC)
Number of subjects: 172
Study 26885697 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 5070)
Number of subjects: 172
Study 25470782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist consultation (B1)
Number of subjects: 135
Study 25470782 — intervention group
Group type: COMPARATOR
Intervention: Control group (B0)
Number of subjects: 135
Study 22445192 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) for 12 weeks
Number of subjects: 37
Study 22445192 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (control)
Number of subjects: 37
Study 21989041 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused shockwave therapy
Number of subjects: 0
Study 21989041 — intervention group
Group type: COMPARATOR
Intervention: Radial shockwave therapy
Number of subjects: 0
Study 21989041 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Focused and Radial shockwave therapy)
Number of subjects: 0
Study 17935212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 985
Study 17935212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 985
Study 17935212 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT-6 subscale
Number of subjects: 985
Study 17935212 — intervention group
Group type: EXPERIMENTAL
Intervention: Maier Philipp subscale
Number of subjects: 985
Study 16930211 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (2 tablets of 333 mg t.i.d.)
Number of subjects: 24
Study 16930211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19667667 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 300000
Study 11124307 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination dorzolamide 2% and timolol 0.5% therapy
Number of subjects: 74
Study 11124307 — intervention group
Group type: COMPARATOR
Intervention: Concomitant administration of a topical beta-blocker and dorzolamide
Number of subjects: 74
Study 9267375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush and Ayre spatula
Number of subjects: 222
Study 9267375 — intervention group
Group type: COMPARATOR
Intervention: Dacron swab and Ayre spatula
Number of subjects: 222
Study 8228194 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sodium restriction (20 mmol/day)
Number of subjects: 188
Study 8228194 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sodium restriction (85 mmol/day)
Number of subjects: 188
Study 8228194 — intervention group
Group type: COMPARATOR
Intervention: Control (300 mmol/day sodium)
Number of subjects: 188
Study 8228194 — intervention group
Group type: COMPARATOR
Intervention: Control (200 mmol/day sodium)
Number of subjects: 188
Study 3027300 — intervention group
Group type: EXPERIMENTAL
Intervention: U-62,066E (2, 3, 4, 5, or 6 micrograms/kg)
Number of subjects: 0
Study 3027300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3027300 — intervention group
Group type: EXPERIMENTAL
Intervention: U-62,066E
Number of subjects: 0
Study 28992224 — intervention group
Group type: EXPERIMENTAL
Intervention: High cut‐off (HCO) dialysis
Number of subjects: 0
Study 28992224 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium cut‐off (MCO) dialysis
Number of subjects: 0
Study 28992224 — intervention group
Group type: COMPARATOR
Intervention: High-flux (HF) dialysis
Number of subjects: 0
Study 28992224 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro dialysis sera from HCO and MCO patients
Number of subjects: 0
Study 28992224 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro dialysates from HCO and MCO
Number of subjects: 0
Study 27788130 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo pill (Study 1, 2 weeks)
Number of subjects: 56
Study 27788130 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo pill (Study 2, 3 months)
Number of subjects: 56
Study 27788130 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (Study 2, 3 months)
Number of subjects: 56
Study 27788130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Study 1)
Number of subjects: 56
Study 27788130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Study 2)
Number of subjects: 56
Study 27788130 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (Study 2)
Number of subjects: 56
Study 25022840 — intervention group
Group type: EXPERIMENTAL
Intervention: 17DD-YF vaccine subdose of 587 IU
Number of subjects: 0
Study 25022840 — intervention group
Group type: EXPERIMENTAL
Intervention: 17DD-YF vaccine subdose of 3,013 IU
Number of subjects: 0
Study 25022840 — intervention group
Group type: COMPARATOR
Intervention: Current dose of 17DD-YF vaccine (27,476 IU)
Number of subjects: 0
Study 23082576 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil dentifrice
Number of subjects: 104
Study 23082576 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 104
Study 15661551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment (2 years)
Number of subjects: 564
Study 15661551 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 564
Study 12464864 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral intake of a formula enriched with arginine and n‐3 fatty acids for 5 days before surgery (pre‐op group)
Number of subjects: 200
Study 12464864 — intervention group
Group type: EXPERIMENTAL
Intervention: Same preoperative treatment prolonged after surgery by jejunal infusion (peri‐op group)
Number of subjects: 200
Study 12464864 — intervention group
Group type: COMPARATOR
Intervention: Standard isoenergetic, isonitrogenous formula for 5 days before surgery (control group)
Number of subjects: 200
Study 12464864 — intervention group
Group type: COMPARATOR
Intervention: No supplementation before and after operation (conventional group)
Number of subjects: 200
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.d.
Number of subjects: 32
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg b.d.
Number of subjects: 32
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d.
Number of subjects: 32
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg t.d.s.
Number of subjects: 32
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg o.d.
Number of subjects: 32
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg b.d.
Number of subjects: 32
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg t.d.s.
Number of subjects: 32
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d. and t.d.s.
Number of subjects: 32
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg b.d. and t.d.s.
Number of subjects: 32
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg t.d.s., 60 mg b.d. and 60 mg t.d.s.
Number of subjects: 32
Study 9690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-regimen serum gastrin values
Number of subjects: 32
Study 8845493 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation therapy
Number of subjects: 0
Study 8845493 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy management
Number of subjects: 0
Study 2712613 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroids
Number of subjects: 62
Study 2712613 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 62
Study 2712613 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (local steroids + physiotherapy)
Number of subjects: 62
Study 582550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium sulphate (24‐36 mval/d)
Number of subjects: 24
Study 582550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28531361 — intervention group
Group type: EXPERIMENTAL
Intervention: EV 4 mg
Number of subjects: 39
Study 28531361 — intervention group
Group type: EXPERIMENTAL
Intervention: EV 9 mg
Number of subjects: 39
Study 28531361 — intervention group
Group type: COMPARATOR
Intervention: EV 4 mg and EV 9 mg
Number of subjects: 39
Study 28116437 — intervention group
Group type: EXPERIMENTAL
Intervention: Microabrasion before LED whitening
Number of subjects: 112
Study 28116437 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment of Beyond LED whitening and fluoride removal agent
Number of subjects: 112
Study 28116437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 24955610 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month lifestyle plus metformin intervention
Number of subjects: 56
Study 24955610 — intervention group
Group type: COMPARATOR
Intervention: Control group (adolescents who increased their %BF)
Number of subjects: 56
Study 22782367 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic large‐pore lightweight mesh
Number of subjects: 36
Study 22782367 — intervention group
Group type: COMPARATOR
Intervention: No mesh (control group)
Number of subjects: 36
Study 22782367 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fat thickness ≥23 mm
Number of subjects: 36
Study 22782367 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a mesh
Number of subjects: 36
Study 20103777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokalemia (serum potassium <4 mEq/L)
Number of subjects: 2793
Study 20103777 — intervention group
Group type: COMPARATOR
Intervention: Normokalemia (4 to 4.9 mEq/L)
Number of subjects: 2793
Study 20103777 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypokalemia (3.5 to 3.9 mEq/L)
Number of subjects: 2793
Study 20103777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokalemia (<4 mEq/L)
Number of subjects: 2793
Study 20409883 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0
Study 20409883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16131699 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index (HGI) meal
Number of subjects: 8
Study 16131699 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic index (LGI) meal
Number of subjects: 8
Study 11911511 — intervention group
Group type: EXPERIMENTAL
Intervention: Axilla hold
Number of subjects: 22
Study 11911511 — intervention group
Group type: COMPARATOR
Intervention: Distal hold
Number of subjects: 22
Study 10430251 — intervention group
Group type: EXPERIMENTAL
Intervention: XRT (breast irradiation)
Number of subjects: 623
Study 10430251 — intervention group
Group type: COMPARATOR
Intervention: Control (no XRT)
Number of subjects: 623
Study 7776510 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine alone (group A)
Number of subjects: 60
Study 7776510 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine 5 micrograms in 1 ml of 0.25% bupivacaine (group B)
Number of subjects: 60
Study 7776510 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine 8 micrograms in 1 ml of 0.25% bupivacaine (group C)
Number of subjects: 60
Study 7776510 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine 12 micrograms in 1 ml of 0.25% bupivacaine (group D)
Number of subjects: 60
Study 7776510 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine 15 micrograms in 1 ml of 0.25% bupivacaine (group E)
Number of subjects: 60
Study 7776510 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine 18 micrograms in 1 ml of 0.25% bupivacaine (group F)
Number of subjects: 60
Study 2335446 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 2335446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 378140 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative administration of cefamandole plus five days of placebo
Number of subjects: 220
Study 378140 — intervention group
Group type: COMPARATOR
Intervention: Perioperative plus five days of postoperative antibiotic therapy
Number of subjects: 220
Study 378140 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative therapy alone
Number of subjects: 220
Study 378140 — intervention group
Group type: COMPARATOR
Intervention: Perioperative plus 5-7 days of postoperative treatment
Number of subjects: 220
Study 378140 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative infection
Number of subjects: 220
Study 378140 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate prophylactic antibiotic
Number of subjects: 220
Study 31741356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 1640
Study 31741356 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1640
Study 25347930 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide mucoadhesive film
Number of subjects: 60
Study 25347930 — intervention group
Group type: COMPARATOR
Intervention: Licorice mucoadhesive film
Number of subjects: 60
Study 25394316 — intervention group
Group type: EXPERIMENTAL
Intervention: Roland-Morris Disability Questionnaire (RMDQ)
Number of subjects: 457
Study 23351013 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF withdrawal (2 g/d)
Number of subjects: 39
Study 23351013 — intervention group
Group type: COMPARATOR
Intervention: CsA withdrawal
Number of subjects: 39
Study 23351013 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF group
Number of subjects: 39
Study 23351013 — intervention group
Group type: COMPARATOR
Intervention: CsA group
Number of subjects: 39
Study 21069309 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg tolterodine (twice a day)
Number of subjects: 80
Study 21069309 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (control group)
Number of subjects: 80
Study 19587891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Kin antisarro dentifrice (0.32% sodium fluoride, 4.1% tetrapotassium pyrophosphate, 2.0% PVM/MA copolymer, 1.0% provitamin B5, 0.2% vitamin B3) used twice a day for 2 minutes for 3 months
Number of subjects: 48
Study 17459739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide treatment for 6 months
Number of subjects: 14
Study 17459739 — intervention group
Group type: COMPARATOR
Intervention: Medication-free lead-in period for 3 months
Number of subjects: 14
Study 16316358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (300 mg)
Number of subjects: 38
Study 16316358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11152855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0
Study 11152855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9624242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy (cisplatin and etoposide)
Number of subjects: 58
Study 9624242 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 58
Study 7828190 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral sumatriptan (group I)
Number of subjects: 1246
Study 7828190 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group II)
Number of subjects: 1246
Study 7828190 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral sumatriptan (group I) for treating headache recurrence
Number of subjects: 1246
Study 7828190 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group II) for treating headache recurrence
Number of subjects: 1246
Study 3254614 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (0.25, 0.5, 1.0, or 2.0 mg)
Number of subjects: 30
Study 3254614 — intervention group
Group type: EXPERIMENTAL
Intervention: G-(1-21) (0.175, 0.35, 0.70, or 1.4 mg)
Number of subjects: 30
Study 3254614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29658845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 29658845 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 26091812 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass graft surgery (OPCABG)
Number of subjects: 0
Study 26091812 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass graft surgery (ONCABG)
Number of subjects: 0
Study 26218935 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitacre needle
Number of subjects: 149
Study 26218935 — intervention group
Group type: COMPARATOR
Intervention: Quincke needle
Number of subjects: 149
Study 23939351 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (Hb trigger, 70 g/L; target, 71-90 g/L)
Number of subjects: 100
Study 23939351 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (Hb trigger, 90 g/L; target, 91-110 g/L)
Number of subjects: 100
Study 23939351 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of restrictive vs liberal
Number of subjects: 100
Study 20888255 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (Group 2)
Number of subjects: 47
Study 20888255 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (Group 1)
Number of subjects: 47
Study 19180322 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+Loxoprofen
Number of subjects: 60
Study 19180322 — intervention group
Group type: COMPARATOR
Intervention: SRP+placebo
Number of subjects: 60
Study 16600984 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1500 mg/m²) followed by oxaliplatin (85 mg/m²) on day 1 and 15 of a 28-day cycle
Number of subjects: 30
Study 16600984 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-oxaliplatin (GEMOX) combination
Number of subjects: 30
Study 12744112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel (harmonic scalpel)
Number of subjects: 142
Study 12744112 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 142
Study 11001084 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist asthma nurse intervention with three 6-weekly outpatient appointments for structured asthma consultation.
Number of subjects: 211
Study 8644382 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 80
Study 8644382 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 80
Study 8644382 — intervention group
Group type: COMPARATOR
Intervention: Myelography
Number of subjects: 80
Study 1993640 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 30
Study 1993640 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 30
Study 1993640 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 15 mg
Number of subjects: 30
Study 1993640 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 30
Study 1993640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6418188 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil with Althesin
Number of subjects: 80
Study 6418188 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate or Fentanyl
Number of subjects: 80
Study 6418188 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 80
Study 6418188 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 80
Study 6418188 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 80
Study 6418188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ease of maintenance of anaesthesia
Number of subjects: 80
Study 30672056 — intervention group
Group type: EXPERIMENTAL
Intervention: Magee Equations
Number of subjects: 175